The MAGNET – Drug Discovery & Quantum
Reality, readiness and the road ahead
Quantum computing is gaining momentum across industries, but its potential in drug discovery is still being defined. While early applications are emerging, key questions remain around technological readiness, commercial value and the gap between genuine progress and hype.Join us at the MAGNET 2026 – Drug Discovery & Quantum: Reality, readiness and the road ahead for an engaging discussion with experts from quantum innovation, AI-driven drug discovery, venture capital, academia and big pharma. Bringing together both advocates and skeptical voices, the event will examine where quantum computing is already creating value, what remains experimental and what organizations should do today to prepare for its future impact.
Discover how to:
-
Evaluate where quantum computing may offer a genuine advantage in drug discovery
-
Compare quantum approaches with established AI and computational methods
-
Prepare for the scientific, commercial and organizational challenges ahead
On stage:
Sabrina Maniscalco, CEO and Co-founder, Algorithmiq
Clément Javerzac, Team Leader Applied Quantum Computing, FHNW
Tobias Denzler, Head of Science and Technology, QAI Ventures
Christian Kramer, Head of Computer-Aided Drug Design (CADD), Roche
Participation is free. However, registration is required before 25 Octobre 2026.
Agenda
Welcome
Keynote
Pannel discussion, followed by Q&A
- Sabrina Maniscalco, Co-founder and CEO, Algorithmiq
- Prof. Dr. Clément Javerzac, Team Leader Applied Quantum Computing, FHNW
- Tobias Denzler, Global Head of Science and Technology, QAI Ventures
- Christian Kramer, Head of Computer-Aided Drug Design (CADD), Roche